Our lead pipeline candidate, etripamil, is a proprietary chemical entity that was conceived, discovered, and optimized by Milestone.

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug, etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT).  Milestone has initiated a Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib with RVR) and expects to subsequently initiate other Phase 2 clinical trials to establish proof-of-concept for the broader use of etripamil in other cardiovascular conditions.

Etripamil is not currently approved for the treatment of PSVT, AFib with RVR, or for any other indication anywhere in the world.